Dr. Brugarolas is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
5323 Harry Hines Boulevard
Dallas, TX 75390Phone+1 214-645-4673Fax+1 214-645-2542
Summary
Clinical Expertise
- Kidney Neoplasms, Renal cell carcinoma, Urologic oncology, Hematologic oncology
Education & Training
- Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2001 - 2003
- Duke University HospitalResidency, Internal Medicine, 1998 - 2001
- Massachusetts Institute of TechnologyPhD, Biology, 1993 - 1998
- Universidad de Navarra Faculty of MedicineClass of 1993
Certifications & Licensure
- TX State Medical License 2006 - 2026
- MA State Medical License 2002 - 2007
- NC State Medical License 1998 - 2004
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Principal Investigator, Kidney Cancer Specialized Program of Research Excellence (SPORE) National Cancer Institute
- Elected to the American Society for Clinical Investigation 2013
- Individual Investigator Research Award Cancer Prevention and Research Institute of Texas, 2010
- Join now to see all
Publications & Presentations
PubMed
- 47 citationsEstablishing a human renal cell carcinoma tumorgraft platform for preclinical drug testingAndrea Pavia-Jimenez, Vanina Tcheuyap, James Brugarolas
Nature Protocols. 2014-08-01 - 25 citationsStereotactic Ablative Radiation for Systemic Therapy-naïve Oligometastatic Kidney Cancer.Raquibul Hannan, Michael Christensen, Alana Christie, Aurelie Garant, Ivan Pedrosa
European Urology Oncology. 2022-12-01 - 39 citationsPhase II Trial of Stereotactic Ablative Radiation for Oligoprogressive Metastatic Kidney Cancer.Raquibul Hannan, Michael Christensen, Hans Hammers, Alana Christie, Brendan Paulman
European Urology Oncology. 2022-04-01
Press Mentions
- Clinical Trials for Kidney Cancer: What to KnowDecember 26th, 2022
- Tackling HIF2 Drug Resistance with an RNA-Based Therapy: NewsroomOctober 3rd, 2022
- Clinical Trial Sets Stage for New Paradigm in Kidney Cancer TreatmentAugust 18th, 2022
- Join now to see all
Grant Support
- Specialized Program of Research Excellence (SPORE)NIH/NCI2016–Present
Committees
- Chair, Scientific Advisory Board, National Kidney Cancer Academy 2020 - Present
- Chair, Congressionally Directed Medical Research Program – Kidney Cancer Research Program 2017 - 2018
Professional Memberships
- Member
- Member
- American Society for Clinical Investigation - ASCIMember
Other Languages
- Spanish
External Links
- Kidney Cancer Programhttp://www.utsouthwestern.edu/kidneycancer
- Brugarolas Labhttp://www.brugarolaslab.com
- Kidney Cancer SPOREhttps://trp.cancer.gov/spores/kidney.htm
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: